Treatment of Human Solid Malignancies with Autologous Activated Lymphocytes and Cimetidine: A Phase II Trial of the Cancer Biotherapy Research Group

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 727-733

  Dillman, Robert O ^a   Soori, Gamini ^b   DePriest, Carol ^a   Nayak, Shankar K ^a   Beutel, Linda D ^a   Schiltz, Patric M ^a   De Leon, Cristina ^a   O'Connor, Audrey A ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Bergen Mercy Hospital   (United States)

Author keywords

Adoptive cell therapy; Autologous activated lymphocytes; Autolymphocyte therapy; Colorectal cancer; Renal cell cancer

Indexed keywords

CIMETIDINE; CORTICOSTEROID; DIPHENHYDRAMINE; GRANISETRON; HYDROMORPHONE; INDOMETACIN; LORAZEPAM; MONOCLONAL ANTIBODY CD3; PARACETAMOL; RETINOIC ACID;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CELL POPULATION; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CRYOPRESERVATION; CULTURE MEDIUM; FEMALE; FREEZING; HELPER CELL; HUMAN; IN VITRO STUDY; KIDNEY CANCER; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA; SOLID TUMOR; STOMACH CANCER; SWEAT GLAND CANCER; TREATMENT OUTCOME;

EID: 0242581523     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418274     Document Type: Article

References (17)

1. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622.
2. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine activated killer cells for advanced cancer: A National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233.
3. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159.
4. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma: A National Biotherapy Study Group trial. Cancer 1991;68:1.
5. Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother 1994;9:183.
6. Osband ME, Lavin PT, Babayan RK, et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990;335:994.
7. Mavligit GM. Immunologic effects of cimetidine: Potential uses. Pharmacotherapy 1987;7:120S.
8. Krane RJ, Carpiito GA, Ross SD, et al. Treatment of metastatic renal cell carcinoma with autolymphocyte therapy. Low toxicity outpatient approach to adoptive immunotherapy without use of in vivo interleukin-2. Urology 1990;35:417.
9. Lavin PT, Maar R, Franklin M, et al. Autolymphocyte therapy for metastatic renal cell carcinoma: Initial clinical results from 335 patients treated in a multisite clinical practice. Transplant Proc 1992;24:3059.
10. Gold JE, Ross SD, Krellenstein DJ, et al. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: Results in 36 patients. Eur J Cancer 1995;31A:698.
11. Dillman RO, Crispin R, Oldham RK. The Cancer Biotherapy Research Group (CBRG) (formerly the National Biotherapy Study Group [NBSG]): A 10-year perspective. Cancer Biother Radiopharm 1997;12:229.
12. Nayak SK, Beutel L, Irani S, Dillman RO. Characterization of autologous activated lymphocytes being used for adoptive immunotherapy of cancer [abstr. 2864]. Proc Am Assoc Cancer Res 1995;36:481.
13. Schwartz MR, Schiltz PM, Nayak S, et al. Ex vivo activated autologous lymphocytes for use in outpatient cancer therapy [abstr.]. J Immunother 1998;21:465.
14. Cornforth AN, Schiltz PM, Nayak SK, Dillman RO. Characterisation of autologous activated lymphocytes used for adoptive immunotherapy of renal cell and colon carcinoma [abstr.]. J Immunother 2001;24:S4.
15. Kessler DA, Siegel JP, Hoguchi PD, et al. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med 1993;329:1169.
16. Fyfe GA, Fisher RI, Rosenberg SA, et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410.
17. Dillman RO. What to do with IL-2? Cancer Biother Radiopharm 1999;14:423.